Drug intelligence / Profile preview

nab-paclitaxel + nedaplatin + pembrolizumab

Development stage: Preclinical
Lead developer: Bristol Myers Squibb
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Intravenous

Overview

A combination therapy regimen consisting of nab-paclitaxel (an albumin-bound form of paclitaxel), nedaplatin (a platinum-based chemotherapy agent), and pembrolizumab (an anti-PD-1 immunotherapy). This combination leverages multiple mechanisms of action: nab-paclitaxel stabilizes microtubules in cancer cells to inhibit cell division, nedaplatin forms DNA crosslinks to prevent cancer cell replication, and pembrolizumab blocks the PD-1 pathway to enhance T-cell immune response against cancer cells.

Targets

MicrotubuleDNAPDCD1 (Programmed cell death protein 1 receptor)

Beyond the preview

Go deeper on nab-paclitaxel + nedaplatin + pembrolizumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on nab-paclitaxel + nedaplatin + pembrolizumab.

Explore the full profile